高压氧联合贝利尤单抗治疗系统性红斑狼疮72例疗效观察  

Clinical efficacy of hyperbaric oxygen combined with belimumab in the treatment of 72 cases of systemic lupus erythematosus

作　　者：唐玉萍[1] 王玲 石磊[1] 高飞[1] 魏伟 Tang Yuping;Wang Ling;Shi Lei;Gao Fei;Wei Wei(Department of Rheumatology and Immunology,The Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Blood Purification Center,Shanxi Bethune Hospital,Taiyuan 030032,China;Department of General Surgery,The Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二医院风湿免疫科,太原030001 [2]山西白求恩医院血液净化中心,太原030032 [3]山西医科大学第二医院普外科,太原030001

出　　处：《中华航海医学与高气压医学杂志》2025年第2期175-179,共5页Chinese Journal of Nautical Medicine and Hyperbaric Medicine

基　　金：山西省基础研究计划项目(20210302123281);山西医科大学第二医院科研项目(202004-3)。

摘　　要：目的:探讨高压氧联合贝利尤单抗治疗系统性红斑狼疮(SLE)的临床疗效。方法:选取2020年1月至2023年1月山西医科大学第二医院风湿免疫科收治的144例SLE患者作为研究对象。按照随机数字表法分为观察组和对照组,每组72例。对照组患者采用贝利尤单抗综合治疗,观察组患者在对照组的基础上联合高压氧治疗。采用化学发光免疫分析仪检测2组患者治疗前后血清免疫球蛋白(Ig)A、IgM、IgG水平;采用双抗体夹心酶联免疫吸附法检测2组患者血清单核细胞趋化蛋白4(MCP4)、可溶性白细胞介素-2受体(sIL-2R)水平;采取电化学发光法检测2组患者治疗前后血清肌酐(Cr)、血尿素氮(BUN)水平;采取系统性红斑狼疮疾病活动度量表(SLEDAI)评估2组患者治疗后的临床疗效,并统计不良反应。结果:与治疗前比较,2组患者治疗后血清IgA、IgM、IgG、MCP4、sIL-2R、Cr、BUN水平及SLEDAI评分均明显降低,且治疗后观察组均明显低于对照组(P<0.05或P<0.01)。观察组患者不良反应发生率(5.56%,4/72)与对照组(8.33%,6/72)比较差异无统计学意义(χ^(2)=0.030,P=0.864)。结论:高压氧联合贝利尤单抗治疗SLE患者的疗效较好,可明显改善患者免疫功能指标,提高肾功能,降低SLE疾病活动度,且安全性较高。Objective:To investigate the clinical efficacy of hyperbaric oxygen combined with belimumab in the treatment of systemic lupus erythematosus(SLE).Methods:A total of 144 SLE patients admitted to Department of Rheumatology and Immunology of The Second Hospital of Shanxi Medical University between January 2020 and January 2023 were selected as the research subjects.They were divided into an observation group and a control group(72 cases in each group)according to a random number table.The control group received comprehensive belimumab treatment;while the observation group were given a hyperbaric oxygen therapy additionally.The levels of serum immunoglobulin(Ig)A,IgM,and IgG in both groups were measured by a chemiluminescence analyzer before and after treatment.The levels of serum monocyte chemoattractant protein 4(MCP4)and soluble interleukin-2 receptor(sIL-2R)were measured using a double antibody sandwich enzyme-linked immunosorbent assay.The levels of serum creatinine(Cr)and blood urea nitrogen(BUN)in both groups were measured by using electrochemiluminescence before and after treatment.The Systemic Lupus Erythematosus Disease Activity Inventory(SLEDAI)was used to evaluate the clinical efficacy of the treatments for both groups,and adverse reactions were also recorded.Results:The levels of serum IgA,IgM,IgG,MCP4,sIL-2R,Cr,BUN,and SLEDAI scores in both groups were significantly reduced after treatment;and those of the observation group was significantly lower than the control group after treatment(P<0.05 or P<0.01).There was no statistically significant difference in the incidence of adverse reactions between the observation group(5.56%,4/72)and the control group(8.33%,6/72)(χ^(2)=0.030,P=0.864).Conclusion:The use of hyperbaric oxygen combined with belimumab in the treatment of SLE patients has significant therapeutic effects.It can significantly improve patients’immune function indicators,enhance renal function,and reduce SLE disease activity,while maintaining high safety.

关 键 词：系统性红斑狼疮 贝利尤单抗 高压氧 肾功能 免疫学指标 

分 类 号：R59[医药卫生—内科学]